XML 103 R87.htm IDEA: XBRL DOCUMENT v3.21.1
Note 16 - Segment Data - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2019
Revenues [1]                 $ 133,937 $ 117,687 $ 103,135
Gross profit $ 24,736 $ 20,653 $ 21,285 $ 20,340 $ 18,769 $ 14,803 $ 15,586 $ 16,204 87,014 65,362 60,916
Operating expenses                 74,656 57,439 51,135
Operating income                 12,358 7,923 9,781
Nonoperating expense, net                 (10,055) (4,061) (1,158)
Earnings before income taxes                 2,303 3,862 8,623
Depreciation and amortization                 17,660 12,990 9,428
Capital expenditures                 1,992 1,498 1,262
Operating Segments [Member]                      
Revenues [1]                 133,937 115,224 96,228
Gross profit                 87,017 64,944 60,309
Operating expenses                 74,656 57,439 51,135
Operating income                 12,358 7,923 9,781
Nonoperating expense, net                 10,055 4,061 1,158
Depreciation and amortization                 2,704 2,081 1,381
Capital expenditures                 843 890 694
Operating Segments [Member] | Sterilization and Disinfection Control [Member]                      
Revenues [1]                 53,119 49,660 46,297
Gross profit                 39,870 35,797 31,861
Depreciation and amortization                 857 902 902
Capital expenditures                 136 291 384
Operating Segments [Member] | Instruments [Member]                      
Revenues [1]                 32,465 37,984 36,125
Gross profit                 20,158 24,247 22,866
Depreciation and amortization                 164 179 207
Capital expenditures                 128 165 56
Operating Segments [Member] | Biopharmaceutical Development [Member]                      
Revenues [1]                 33,892 13,851 0
Gross profit                 21,035 382 0
Depreciation and amortization                 1,427 672 0
Capital expenditures                 539 233 0
Operating Segments [Member] | Cold Chain Monitoring [Member]                      
Revenues [1]                 14,461 13,729 13,806
Gross profit                 5,954 4,518 5,582
Depreciation and amortization                 256 328 272
Capital expenditures                 40 201 254
Corporate, Non-Segment [Member]                      
Revenues [2]                 0 2,463 6,907
Gross profit [2]                 (3) 418 607
Depreciation and amortization [3]                 14,956 10,909 8,047
Capital expenditures                 $ 1,149 $ 608 $ 568
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Non-reportable operating segments (including our Cold Chain Packaging Division which ceased operations during the year ended March 31, 2020) and unallocated corporate expenses are reported within Corporate and Other.
[3] Amortization of intellectual property is included in the calculation of gross margin by segment. Amortization pertaining to other types of intangible assets, such as customer relationships and trademarks, is included in general and administrative on the Consolidated Statements of Income. Within the table above, the depreciation and amortization costs that are included in calculating the gross margin of the noted segment are included; other costs such as amortization that is recorded to general and administrative expense is shown in corporate and other.